Tafinlar (dabrafenib)

**Product type:** Human Prescription Drug

**Active ingredient:** DABRAFENIB MESYLATE

**Strength:** 10 mg/1

**Dosage form:** Tablet, For Suspension

**Route:** Oral

**Labeler:** Novartis Pharmaceuticals Corporation

**Marketing category:** NDA (NDA217514)

**Pharmacologic class:** Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Kinase Inhibitor [EPC], Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Protein Kinase Inhibitors [MoA]